天益医疗融资融券信息显示，融资方面，当日融资买入1680.29万元，融资偿还661.75万元，融资净买入 1018.54万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量0.0股，融券余额0.0万元。融资融 券余额6363.03万元。 近5日融资融券数据一览见下表： 证券之星消息，截至2025年11月19日收盘，天益医疗(301097)报收于58.24元，下跌5.35%，换手率 6.03%，成交量1.75万手，成交额1.02亿元。 11月19日的资金流向数据方面，主力资金净流出230.13万元，占总成交额2.25%，游资资金净流出 308.35万元，占总成交额3.01%，散户资金净流入538.48万元，占总成交额5.26%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-19 | 58.24 -5.35% | | -230.13万 | -2.25% | -308.35 ...

近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-14 | 60.00 -6.29% | 752.24万 | 4.45% | -395.73万 | -2.34% | -356.51万 | -2.11% | | 2025-11-13 | 64.03 -1.94% | -2040.35万 | -7.20% | 1280.76万 | 4.52% | 759.59万 | 2.68% | | 2025-11-12 | 65.30 11.34% | -90.71万 | -0.31% | 1813.46万 | 6.16% | -1722.75万 | -5.85% | | 2025-11-11 | 58.65 -1.56% | -233.23万 | -2.37% | 196.65万 | 1.99% | 36.59万 | 0.37% | | 2025-11-10 | 59.58 7.35% | 450.32万 | ...

中信保诚多策略混合(LOF)A（165531）成立日期2017年6月16日，最新规模11.33亿。今年以来收益 48.93%，同类排名1166/8140；近一年收益46.65%，同类排名762/8056；成立以来收益152.18%。 中信保诚多策略混合(LOF)A（165531）基金经理为王颖。 截至发稿，王颖累计任职时间8年274天，现任基金资产总规模49.04亿元，任职期间最佳基金回报 53.77%， 任职期间最差基金回报-8.42%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月14日，天益医疗跌5.04%，截至发稿，报60.80元/股，成交3032.49万元，换手率1.70%，总市值 35.84亿元。 资料显示，宁波天益医疗器械股份有限公司位于浙江省宁波市东钱湖旅游度假区莫枝北路788号，成立 日期1998年3月12日，上市日期2022年4月7日，公司主营业务涉及血液净化及病房护理领域医用高分子 耗材等医疗器械的研发、生产与销售。主营业务收入构成为：血液 ...

截至10月10日，天益医疗股东户数4042.00，较上期增加4.55%；人均流通股4539股，较上期减少 4.35%。2025年1月-6月，天益医疗实现营业收入2.27亿元，同比增长11.50%；归母净利润948.32万元， 同比减少35.23%。 分红方面，天益医疗A股上市后累计派现1.02亿元。近三年，累计派现8749.78万元。 机构持仓方面，截止2025年6月30日，天益医疗十大流通股东中，鹏华弘嘉混合A（003165）位居第四 大流通股东，持股49.87万股，持股数量较上期不变。圆信永丰聚优A（010469）位居第八大流通股东， 持股28.70万股，相比上期减少2.80万股。圆信永丰医药健康A（006274）位居第十大流通股东，持股 23.00万股，相比上期减少4.55万股。鹏华优质治理混合(LOF)A（160611）退出十大流通股东之列。 责任编辑：小浪快报 10月13日，天益医疗跌0.85%，成交额2546.10万元。两融数据显示，当日天益医疗获融资买入额204.16 万元，融资偿还170.65万元，融资净买入33.50万元。截至10月13日，天益医疗融资融券余额合计 5462.38万元。 融资 ...

Core Insights - Tianyi Medical experienced a 1.18% decline in stock price on September 25, with a trading volume of 26.36 million yuan [1] - The company reported a financing net purchase of 1.32 million yuan on the same day, with a total financing balance of 56.13 million yuan, accounting for 7.15% of its market capitalization [1] - For the first half of 2025, Tianyi Medical achieved a revenue of 227 million yuan, representing a year-on-year growth of 11.50%, while the net profit attributable to shareholders decreased by 35.23% to 9.48 million yuan [2] Financing and Trading Activity - On September 25, Tianyi Medical had a financing buy-in of 4.50 million yuan and a financing repayment of 3.18 million yuan, resulting in a net financing purchase of 1.32 million yuan [1] - The total financing and securities lending balance reached 56.13 million yuan, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - No shares were sold or repaid in the securities lending segment on September 25, with a balance of 0.00 yuan, also reflecting a high percentile level over the past year [1] Company Overview - Tianyi Medical, established on March 12, 1998, and listed on April 7, 2022, specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1] - The company's revenue composition includes 59.05% from blood purification products, 34.08% from ward care products, and 6.87% from other categories [1] Shareholder and Dividend Information - As of June 30, 2025, Tianyi Medical had 4,196 shareholders, a slight decrease of 0.31%, with an average of 4,372 circulating shares per person, an increase of 0.31% [2] - The company has distributed a total of 102 million yuan in dividends since its A-share listing, with 87.50 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders, Penghua Hongjia Mixed A remains the fourth largest, holding 498,700 shares, while other funds have seen reductions in their holdings [3]

Core Viewpoint - Tianyi Medical has experienced a decline in stock price, with a 5.05% drop on September 19, 2023, and a cumulative decline of 4.3% over three consecutive days [1] Company Overview - Tianyi Medical, established on March 12, 1998, is located in Ningbo, Zhejiang Province, and was listed on April 7, 2022. The company specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1] - The revenue composition of Tianyi Medical is as follows: blood purification accounts for 59.05%, ward care for 34.08%, and other products for 6.87% [1] Shareholder Information - Among the top ten circulating shareholders, Penghua Fund's Penghua Hongjia Mixed A (003165) holds 498,700 shares, unchanged from the previous period, representing 2.72% of circulating shares. The estimated floating loss today is approximately 1.12 million yuan, with a cumulative floating loss of 997,400 yuan over the three-day decline [2] - Penghua Hongjia Mixed A has a total scale of 450 million yuan and has achieved a year-to-date return of 34.51%, ranking 2279 out of 8172 in its category [2] Fund Manager Performance - The fund manager of Penghua Hongjia Mixed A is Tang Zhiyuan, who has been in the position for 8 years and 69 days. The fund's total asset scale is 1.378 billion yuan, with the best return during his tenure being 177.74% and the worst being -3.8% [3][5] Fund Holdings - Penghua Anjin One-Year Holding Period Mixed A (017083) is another fund under Penghua Fund that has a significant holding in Tianyi Medical, with 66,400 shares, accounting for 1.57% of the fund's net value. The estimated floating loss today is about 149,400 yuan, with a cumulative floating loss of 132,800 yuan over the three-day decline [4] - This fund was established on March 14, 2023, with a total scale of 125 million yuan, achieving a year-to-date return of 12.25%, ranking 5434 out of 8172 in its category [4]

责任编辑：小浪快报 截至6月30日，天益医疗股东户数4196.00，较上期减少0.31%；人均流通股4372股，较上期增加0.31%。 2025年1月-6月，天益医疗实现营业收入2.27亿元，同比增长11.50%；归母净利润948.32万元，同比减少 35.23%。 分红方面，天益医疗A股上市后累计派现1.02亿元。近三年，累计派现8749.78万元。 机构持仓方面，截止2025年6月30日，天益医疗十大流通股东中，鹏华弘嘉混合A（003165）位居第四 大流通股东，持股49.87万股，持股数量较上期不变。圆信永丰聚优A（010469）位居第八大流通股东， 持股28.70万股，相比上期减少2.80万股。圆信永丰医药健康A（006274）位居第十大流通股东，持股 23.00万股，相比上期减少4.55万股。鹏华优质治理混合(LOF)A（160611）退出十大流通股东之列。 9月8日，天益医疗盘中上涨2.08%，截至09:48，报45.14元/股，成交393.43万元，换手率0.48%，总市值 26.61亿元。 天益医疗今年以来股价涨25.00%，近5个交易日涨2.13%，近20日跌4.73%，近60日涨15.71 ...

Summary of Key Points Core Viewpoint - Tianyi Medical's stock experienced a decline of 2.77% on August 28, with a trading volume of 66.35 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing and Trading Data - On August 28, Tianyi Medical had a financing purchase amount of 10.72 million yuan and a net financing purchase of 5.96 million yuan, with a total financing and securities balance of 31.14 million yuan, accounting for 3.83% of its market capitalization [1]. - The financing balance is above the 80th percentile of the past year, indicating a high level of financing activity [1]. - There were no short sales or repayments on the same day, with the short selling balance also at zero, placing it in the 90th percentile of the past year [1]. Company Overview - Tianyi Medical, established on March 12, 1998, and listed on April 7, 2022, specializes in the research, production, and sales of medical devices, particularly in blood purification and ward care [1]. - The company's revenue composition includes 59.05% from blood purification, 34.08% from ward care, and 6.87% from other sources [1]. Financial Performance - For the first half of 2025, Tianyi Medical reported a revenue of 227 million yuan, reflecting a year-on-year growth of 11.50%, while the net profit attributable to shareholders decreased by 35.23% to 9.48 million yuan [2]. - The total number of shareholders as of June 30 was 4,196, a slight decrease of 0.31%, with an average of 4,372 circulating shares per person, which increased by 0.31% [2]. Dividend and Shareholder Information - Since its A-share listing, Tianyi Medical has distributed a total of 102 million yuan in dividends, with 87.50 million yuan distributed over the past three years [3]. - As of June 30, 2025, the top ten circulating shareholders included notable funds, with some holdings remaining stable while others saw slight reductions [3].

Summary of Key Points Core Viewpoint - Tianyi Medical (301097) has shown a significant increase in stock price, closing at 48.4 yuan on July 25, 2025, with a rise of 4.85% [1] Financial Performance - The company reported a main revenue of 98.51 million yuan in Q1 2025, reflecting a year-on-year increase of 1.65% [5] - The net profit attributable to shareholders was 4.88 million yuan, a decrease of 9.81% year-on-year [5] - The company experienced a negative non-recurring net profit of -520,700 yuan, down 123.38% year-on-year [5] - The gross profit margin stood at 33.25% [5] Market Activity - On July 25, 2025, the net inflow of main funds was 4.05 million yuan, accounting for 2.98% of the total transaction amount [1][2] - Retail investors contributed a net inflow of 3.07 million yuan, representing 2.26% of the total transaction amount [1][2] - The stock had a turnover rate of 15.33% on the same day, with a total transaction volume of 28,100 hands and a transaction amount of 136 million yuan [1] Financing and Margin Trading - On July 25, 2025, the financing balance was 39.70 million yuan, with a net financing purchase of 1.70 million yuan [3] - There were no shares sold or repaid in the margin trading segment, indicating no activity in this area [3] Industry Comparison - Tianyi Medical's total market value is 2.853 billion yuan, significantly lower than the industry average of 11.518 billion yuan [5] - The company's net asset value is 1.194 billion yuan, compared to the industry average of 3.919 billion yuan [5] - The price-to-earnings ratio (P/E) is 146.28, which is considerably higher than the industry average of 63.28 [5] - The net profit margin of 4.95% is below the industry average of 10.86% [5]